Already, survival in typically aged multiple myeloma (MM) patients has been pushed to "six, seven, maybe eight or nine years sometimes," Christophe Bianchi, president of Takeda Oncology, told BioWorld Today, and the space "keeps getting more crowded, which is good news for patients."